Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP
June 11, 2019 08:30 ET
|
Cyclerion Therapeutics, Inc.
– Series of preclinical studies provide further rationale for study of IW-6463 as a potential treatment for neurodegenerative diseases – – Preclinical data provide insights into...
Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings
June 04, 2019 08:30 ET
|
Cyclerion Therapeutics, Inc.
– In preclinical study, treatment with company’s investigational sGC stimulator olinciguat was associated with improved blood flow and reduced inflammation in a model of sickle cell disease – – New...
Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company
May 13, 2019 07:00 ET
|
Cyclerion Therapeutics, Inc.
– Completed enrollment in Phase 2 studies of praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) – – Based on encouraging tolerability data, company intends...
Cyclerion to Host Corporate Overview Call on May 13, 2019
April 25, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion Announces the Appointment of Andreas Busch, Ph.D., as Chief Innovation Officer
April 09, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases
April 02, 2019 08:00 ET
|
Cyclerion Therapeutics, Inc.
– $175 million committed from investors in private placement offering – – Trading of CYCN begins on Nasdaq today – CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics,...
GBT Announces New Employment Inducement Grants
November 06, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 1, 2018, the compensation...
GBT Announces New Employment Inducement Grants
October 04, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on October 1, 2018, the compensation committee of the...
GBT Announces Participation at the 2018 Cantor Global Healthcare Conference
September 26, 2018 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Cantor Global Healthcare...
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
January 09, 2018 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted...